Crescita Therapeutics Inc. (TSE:CTX – Get Free Report) shares rose 1.8% on Monday . The stock traded as high as C$0.58 and last traded at C$0.58. Approximately 3,525 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 5,882 shares. The stock had previously closed at C$0.57.
Crescita Therapeutics Stock Up 1.8 %
The company has a debt-to-equity ratio of 6.02, a quick ratio of 2.29 and a current ratio of 3.37. The firm has a market capitalization of C$11.24 million, a P/E ratio of -3.87 and a beta of 1.69. The stock has a fifty day moving average price of C$0.58 and a two-hundred day moving average price of C$0.59.
Insiders Place Their Bets
In related news, Director Jose Darocha acquired 86,000 shares of Crescita Therapeutics stock in a transaction that occurred on Friday, December 27th. The stock was acquired at an average price of C$0.60 per share, for a total transaction of C$51,436.60. 10.87% of the stock is owned by corporate insiders.
About Crescita Therapeutics
Crescita Therapeutics Inc, a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp.
Featured Stories
- Five stocks we like better than Crescita Therapeutics
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- How to Choose Top Rated Stocks
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Crescita Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescita Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.